Evidence map›Paper›PMID 32815051›Full record

ArticleThe international journal of cardiovascular imaging2021

Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.

Mustafa Yenerçağ, Uğur Arslan, Seçkin Dereli, Metin Çoksevim, Mustafa Doğduş, Ahmet Kaya

Abstract read
PubMed Publisher
In one paragraph

Article in The international journal of cardiovascular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Novel Therapies for Right Ventricular Failure.Current cardiology reports · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Mustafa YenerçağDepartment of Cardiology, University of Health Sciences Samsun Training and Research Hospital, Baris Bulvari, No: 199, 55400, Samsun, Turkey.
Uğur ArslanDepartment of Cardiology, University of Health Sciences Samsun Training and Research Hospital, Baris Bulvari, No: 199, 55400, Samsun, Turkey. ugurarslan5@yahoo.com.ORCID http://orcid.org/0000-0001-8572-3571
Seçkin DereliDeparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey.
Metin ÇoksevimDeparment of Cardiology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey.
Mustafa DoğduşDepartment of Cardiology, University of Usak Training and Research Hospital, Usak, Turkey.
Ahmet KayaDeparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey.
Ordu University · TRSamsun University · TROndokuz Mayıs University · TRUsak University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sacubitril/valsartan combination is an important agent used in the treatment of heart failure with reduced ejection fraction (HFrEF). Pulmonary artery stiffness (PAS) is an index developed to evaluate the pulmonary vascular bed. Changes in pulmonary vascular structures in HFrEF patients can affect PAS. In this study, we aimed to investigate the effect of sacubitril/valsartan on PAS in HFrEF patients. One hundred fifty HFrEF patients, who received sacubitril/valsartan therapy and continued for at least 6 months without interruption, were examined retrospectively. N-terminal pro-B-type natriuretic peptide levels (NT-proBNP), NYHA classes, Minnesota Living with Heart Failure Questionnaire (MLWHFQ) scores, New York Heart Association (NYHA) functional classes and echocardiograpic parameters such as left ventricular ejection fraction (LVEF), mean pulmonary artery pressure (mPAP), right ventricle myocardial performance index (RV-MPI), Tricuspid annular plane systolic excursion (TAPSE), right ventricular fractional area change (RV-FAC) and PAS changes were evaluated before and 6 months after sacubitril/valsartan treatment. PAS was calculated by using the maximal frequency shift and acceleration time of the pulmonary artery flow trace measured in the echocardiogram. PAS values were significantly reduced (23.8 ± 2.8 vs 19.1 ± 3.1 kHz/ms, p < 0.001) after the sacubitril/valsartan treatment. Sacubitril/valsartan treatment was associated with significant improvements in NYHA class and MLWHFQ scores; significant reductions in the NT-proBNP levels, mPAP, and RV-MPI, and significant increases in LVEF, TAPSE, and RV-FAC (p < 0.05). The significant reduction in the PAS value was significantly correlated with the improvements in the MLWFQ scores, NT-proBNP levels, mPAP, RV-MPI, TAPSE and RV-FAC. In HFrEF patients, switching from angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to sacubitril/valsartan may result in reduction in PAS.

Indexed as

AgedAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsCross-Sectional StudiesDrug CombinationsEchocardiography, Doppler, PulsedFemaleHeart FailureHumansMaleMiddle AgedNeprilysinProtease InhibitorsPulmonary ArteryRetrospective StudiesAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsDrug CombinationsNeprilysinProtease Inhibitorssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanHeart failurePulmonary artery stiffnessSacubitril/valsartan

Identifiers

PMID32815051
OpenAlexW3079452946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.